Eli Lilly's Omvoh shows long-term efficacy against ulcerative colitis and Crohn's disease, with high rates of remission ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company , found that over half (60% ...

Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, capturing more than double the market share of its rival two months after launch.

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Over 950 adults with moderate to severe UC were treated with Omvoh. During the induction study, people took Omvoh for 12 weeks. Then, some people who achieved clinical response continued to take ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

In October 2023, the U.S. Food and Drug Administration approved Omvoh® (mirikizumab-mrkz) as a first-in-class treatment for adults with moderately to severely active UC. Omvoh is also approved in ...